Filing Details
- Accession Number:
- 0001209191-18-003434
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-01-12 16:34:11
- Reporting Period:
- 2018-01-10
- Accepted Time:
- 2018-01-12 16:34:11
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1439222 | Agios Pharmaceuticals Inc | AGIO | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1581956 | Scott Biller | C/O Agios Pharmaceuticals, Inc. 88 Sidney Street Cambridge MA 02139 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-01-10 | 3,000 | $0.47 | 56,059 | No | 4 | M | Direct | |
Common Stock | Disposition | 2018-01-10 | 3,000 | $65.00 | 53,059 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock options (right to buy) | Disposition | 2018-01-10 | 3,000 | $0.00 | 3,000 | $0.47 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
1,867 | 2020-12-06 | No | 4 | M | Direct |
Footnotes
- This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- This option was granted on December 7, 2010. The shares underlying this option vested as to 25% of the shares upon the achievement of a performance milestone, and as to the remaining 75% in 36 equal monthly installments thereafter. The performance criteria was met on June 23, 2015.